Current Edition

Optimising the HPAPI Value Chain to Achieve Maximised Product Value

In the quest to find new and more effective treatments against severe diseases, researchers are increasingly moving towards active pharmaceutical ingredients (APIs) with increased potency and more targeted delivery mechanisms. These powerful compounds may help treat life-threatening and so-far incurable diseases, including cancer, diabetes, Parkinson’s disease, and others. Maurits Janssen at Lonza Pharma & Biotech showcases why sustainable manufacturing of highly potent APIs (HPAPIs) requires specific precautions to operator health and safety on the one side and to product quality on the other.